bdb-001
mAbexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Sep 25, 2019 (NCT05360927)
Timeline
Indications
Mechanism of action
C5AR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07168161 | Phase 3 | Nov 10, 2025 | Peking University, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05197842 | Phase 1/Phase 2 (Phase 2) | Feb 22, 2022 | Peking University, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05093855 | Phase 2 | Aug 18, 2021 | Beijing Defengrui Biotechnology Co. Ltd, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05103423 | Phase 1/Phase 2 (Phase 2) | Jun 24, 2021 | Beijing Defengrui Biotechnology Co. Ltd, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT04449588 | Phase 2/Phase 3 (Phase 3) | Jul 23, 2020 | Beijing Defengrui Biotechnology Co. Ltd, Southwest Hospital of Chongqing, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05361005 | Phase 1 | Mar 12, 2020 | Beijing Defengrui Biotechnology Co. Ltd, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05075304 | Phase 1 | Feb 21, 2020 | Beijing Defengrui Biotechnology Co. Ltd, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT05360927 | Phase 1 | Sep 25, 2019 | Beijing Defengrui Biotechnology Co. Ltd, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Staidson (Beijing) Biopharmaceuticals Co., Ltd | For profit | 8 | 8 | 3 | 2019 |
| Beijing Defengrui Biotechnology Co. Ltd | For profit | 6 | 0 | 3 | 2019 |
| Peking University | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Southwest Hospital of Chongqing | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1